Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The last earnings update was 18 days ago. More info.
Add to Portfolio Compare Print
- Denali Therapeutics has significant price volatility in the past 3 months.
DNLI Share Price and Events
7 Day Returns
1 Year Returns
DNLI Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Denali Therapeutics (DNLI) | 0% | -16.1% | -5.9% | 4% | - | - |
| US Biotechs | 0.3% | -1.4% | -4.9% | -4.9% | 3.6% | 11% |
| US Market | -1.4% | -3.9% | 0.2% | 1.6% | 33.2% | 38.2% |
1 Year Return vs Industry and Market
- DNLI outperformed the Biotechs industry which returned -4.9% over the past year.
- DNLI outperformed the Market in United States of America which returned 1.6% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Denali Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $20.73.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Denali Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Denali Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-0.55 |
| NasdaqGS:DNLI Share Price ** | NasdaqGS (2019-05-24) in USD | $20.73 |
| United States of America Biotechs Industry PE Ratio | Median Figure of 35 Publicly-Listed Biotechs Companies | 18.23x |
| United States of America Market PE Ratio | Median Figure of 3,084 Publicly-Listed Companies | 17.44x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Denali Therapeutics.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:DNLI Share Price ÷ EPS (both in USD) = 20.73 ÷ -0.55 |
-37.79x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Denali Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
- Denali Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Denali Therapeutics's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -37.79x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts |
-8.7%per year |
| United States of America Biotechs Industry PEG Ratio | Median Figure of 28 Publicly-Listed Biotechs Companies | 1.22x |
| United States of America Market PEG Ratio | Median Figure of 2,121 Publicly-Listed Companies | 1.51x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Denali Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Denali Therapeutics's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $5.42 |
| NasdaqGS:DNLI Share Price * | NasdaqGS (2019-05-24) in USD | $20.73 |
| United States of America Biotechs Industry PB Ratio | Median Figure of 416 Publicly-Listed Biotechs Companies | 3.17x |
| United States of America Market PB Ratio | Median Figure of 5,207 Publicly-Listed Companies | 1.8x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:DNLI Share Price ÷ Book Value per Share (both in USD) = 20.73 ÷ 5.42 |
3.82x |
* Primary Listing of Denali Therapeutics.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Denali Therapeutics is overvalued based on assets compared to the US Biotechs industry average.
Value checks
We assess Denali Therapeutics's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Denali Therapeutics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Denali Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Denali Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
- Denali Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:DNLI Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts | -8.7% |
| NasdaqGS:DNLI Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts | 20.6% |
| United States of America Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 22.6% |
| United States of America Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 17.7% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.7% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 295 | -123 | -125 | 1 |
| 2022-12-31 | 133 | -239 | -194 | 1 |
| 2021-12-31 | 116 | -197 | -188 | 2 |
| 2020-12-31 | 146 | -114 | -146 | 3 |
| 2019-12-31 | 78 | -90 | -132 | 4 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 133 | -14 | -52 |
| 2018-12-31 | 129 | 50 | -36 |
| 2018-09-30 | 3 | -61 | -137 |
| 2018-06-30 | 2 | -49 | -123 |
| 2018-03-31 | 1 | -24 | -91 |
| 2017-12-31 | -77 | -88 | |
| 2017-09-30 | -77 | -85 | |
| 2017-06-30 | -76 | -93 | |
| 2017-03-31 | -75 | -90 | |
| 2016-12-31 | -72 | -87 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
All data from Denali Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | -1.19 | -0.20 | -2.17 | 2.00 |
| 2022-12-31 | -1.81 | -1.45 | -2.17 | 2.00 |
| 2021-12-31 | -1.70 | -1.14 | -2.02 | 3.00 |
| 2020-12-31 | -1.59 | -0.96 | -2.25 | 5.00 |
| 2019-12-31 | -1.48 | -0.73 | -1.95 | 5.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -0.55 |
| 2018-12-31 | -0.39 |
| 2018-09-30 | -1.78 |
| 2018-06-30 | -2.20 |
| 2018-03-31 | -2.58 |
| 2017-12-31 | -5.89 |
| 2017-09-30 | -9.16 |
| 2017-06-30 | -11.15 |
| 2017-03-31 | -12.24 |
| 2016-12-31 | -13.49 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Denali Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Denali Therapeutics's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Denali Therapeutics has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Denali Therapeutics performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Denali Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Denali Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Denali Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Denali Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 132.72 | -51.55 | 36.09 | |
| 2018-12-31 | 129.16 | -36.24 | 32.35 | |
| 2018-09-30 | 3.48 | -136.66 | 26.37 | 74.46 |
| 2018-06-30 | 2.29 | -123.13 | 21.31 | 74.46 |
| 2018-03-31 | 0.64 | -90.54 | 17.98 | |
| 2017-12-31 | -88.19 | 15.68 | ||
| 2017-09-30 | -84.65 | 13.66 | 16.75 | |
| 2017-06-30 | -93.42 | 13.00 | 39.27 | |
| 2017-03-31 | -89.63 | 12.22 | 54.85 | |
| 2016-12-31 | -86.65 | 11.73 | ||
| 2015-12-31 | -16.79 | 5.11 | 10.07 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Denali Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Denali Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Denali Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Denali Therapeutics's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Denali Therapeutics has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Denali Therapeutics's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Denali Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
- Denali Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Denali Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Denali Therapeutics Company Filings, last reported 1 month ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 516.65 | 71.41 | 485.48 |
| 2018-12-31 | 546.85 | 0.00 | 464.30 |
| 2018-09-30 | 461.18 | 0.00 | 374.96 |
| 2018-06-30 | 490.27 | 0.00 | 372.59 |
| 2018-03-31 | 539.03 | 0.00 | 373.40 |
| 2017-12-31 | 465.80 | 0.00 | 406.23 |
| 2017-09-30 | 193.14 | 0.00 | 185.80 |
| 2017-06-30 | 213.32 | 0.00 | 186.96 |
| 2017-03-31 | 254.52 | 0.00 | 178.33 |
| 2016-12-31 | 254.52 | 0.00 | 178.33 |
| 2015-12-31 | 32.67 | 0.00 | 30.74 |
- Denali Therapeutics's level of debt (13.8%) compared to net worth is satisfactory (less than 40%).
- Unable to establish if Denali Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Denali Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
- Denali Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -66.1% each year.
Financial health checks
We assess Denali Therapeutics's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Denali Therapeutics has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Denali Therapeutics's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Denali Therapeutics
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Denali Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Denali Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 4 Analyst Estimates (S&P Global) | See Below |
| Global Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 19 Stocks | 2.4% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2007 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | 0.00 | 1.00 |
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Denali Therapeutics has not reported any payouts.
- Unable to verify if Denali Therapeutics's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Denali Therapeutics's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Denali Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Denali Therapeutics has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | $5,983,923 |
| AGE | 42 |
| TENURE AS CEO | 3.8 years |
CEO Bio
Dr. Ryan J. Watts, Ph.D. is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since August 2015. Dr. Watts has been a Director of Denali Therapeutics Inc. since March 2015. From March 2015 to August 2015, Dr. Watts acted as interim President, Chief Scientific Officer and Head of Research and Development of Denali Therapeutics Inc. Dr. Watts served as Director of the Department of Neuroscience at Genentech, where he was employed for 11 years. During his tenure, he led Genetech entry into neuroscience, building a department and advancing multiple programs for neurological disease from discovery to clinical testing. His own laboratory focused on understanding mechanisms of neurodegeneration and on drug discovery for Alzheimer’s disease. He is also a leader in the development of improved methods for delivering therapeutic antibodies across the blood-brain barrier. He obtained his B.S. from the University of Utah and his Ph.D. in biological sciences from Stanford University.
CEO Compensation
- Ryan's compensation has increased whilst company is loss making.
- Ryan's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Denali Therapeutics management team in years:
- The tenure for the Denali Therapeutics management team is about average.
Management Team
Ryan Watts
Co-Founder
$6M
42
3.8 yrs
Alex Schuth
Co-Founder
$4M
45
Marc Tessier-Lavigne
Co-Founder
$405K
58
Steve Krognes
CFO & Treasurer
$4M
50
3.6 yrs
Carole Ho
Chief Medical Officer & Head of Development
$4M
45
3.9 yrs
Dana Andersen
Chief Technical and Manufacturing Officer
0.8 yrs
Chris Walsh
Vice President of Legal
0.3 yrs
Cindy Dunkle
Head of Human Resources
Joe Lewcock
Head of Biology Discovery
Zach Sweeney
Head of Discovery
Board of Directors Tenure
Average tenure and age of the Denali Therapeutics board of directors in years:
- The tenure for the Denali Therapeutics board of directors is about average.
Board of Directors
Vicki Sato
Chairperson
$428K
69
2.8 yrs
Ryan Watts
Co-Founder
$6M
42
4.2 yrs
Marc Tessier-Lavigne
Co-Founder
$405K
58
Peter Klein
Independent Director
$644K
56
1.2 yrs
Doug Cole
Director
$403K
58
4 yrs
Jay Flatley
Director
$404K
65
4.1 yrs
Bob Nelsen
Director
$384K
56
4 yrs
David Schenkein
Director
$404K
61
4.1 yrs
Scott Biller
Member of Scientific Advisory Board
62
Alison Goate
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Denali Therapeutics's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Denali Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?
Today we will look at DNLI’s financial liquidity and debt levels, which are strong indicators for whether the company can weather economic downturns or fund strategic acquisitions for future growth. … Remember this is a very top-level look that focuses exclusively on financial health, so I recommend a deeper analysis. … View our latest analysis for Denali Therapeutics
Simply Wall St - – Full articleIs Denali Therapeutics Inc's (NASDAQ:DNLI) Balance Sheet Strong Enough To Weather A Storm?
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is DNLI growing fast enough to value financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital
Simply Wall St - – Full articleDenali Therapeutics Inc (NASDAQ:DNLI): Time For A Financial Health Check
However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does DNLI's growth rate justify its decision for financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.
Simply Wall St - – Full articleWhat Should We Expect From Denali Therapeutics Inc's (NASDAQ:DNLI) Earnings Over The Next Few Years?
The latest earnings release Denali Therapeutics Inc's (NASDAQ:DNLI) announced in September 2017 showed that losses became smaller relative to the prrior year's level - great news for investors Below is my commentary, albeit very simple and high-level, on how market analysts perceive Denali Therapeutics's earnings growth outlook over the next couple of years and whether the future looks brighter. … NasdaqGS:DNLI Future Profit Jan 11th 18 Although it’s useful to understand the rate of growth each year relative to today’s figure, it may be more valuable evaluating the rate at which the company is growing on average every year. … Future Earnings: How does DNLI's growth rate compare to its peers and the wider market2
Simply Wall St - – Full articleWhat’s Ahead For Denali Therapeutics Inc (NASDAQ:DNLI)?
Check out our latest analysis for Denali Therapeutics What’s the catalyst for Denali Therapeutics's sector growth? … Denali Therapeutics recently delivered an industry-beating growth rate in earnings, which is a positive for shareholders. … However, if you’re relatively concentrated in biotech, you may want to value Denali Therapeutics based on its cash flows to determine if it is overpriced based on its current growth outlook.
Simply Wall St - – Full articleCompany Info
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson’s disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson’s disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer’s disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California.
Details
| Name: | Denali Therapeutics Inc. |
| DNLI | |
| Exchange: | NasdaqGS |
| Founded: | 2013 |
| $1,979,267,045 | |
| 95,478,391 | |
| Website: | http://www.denalitherapeutics.com |
| Address: |
Denali Therapeutics Inc. 161 Oyster Point Boulevard, 2nd Floor, South San Francisco, California, 94080, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | DNLI | Common Stock | Nasdaq Global Select | US | USD | 08. Dec 2017 | |
| DB | 4DN | Common Stock | Deutsche Boerse AG | DE | EUR | 08. Dec 2017 | |
| MUN | 4DN | Common Stock | Boerse Muenchen | DE | EUR | 08. Dec 2017 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/26 00:54 |
| End of day share price update: | 2019/05/24 00:00 |
| Last estimates confirmation: | 2019/05/21 |
| Last earnings filing: | 2019/05/08 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
